Conditions & Recovery · STAT News · July 22, 2026

New study supports testing of Merck’s Ebola vaccine in DRC outbreak

New data supports the idea that Merck’s Ebola vaccine Ervebo, licensed to target the Zaire species of ebolaviruses, could also offer some protection against another.

Originally published by STAT News. We curate and add context; they did the reporting.

Read the full story at STAT News ↗

Related learning

Biotech Firm Claims Some Credit for Groundbreaking Virus Research Biotech Firm Claims Some Credit for Groundbreaking Virus Research James P. Allison, Ph.D., bangs gong after completing proton therapy treatment Combination therapy helps plasmacytoid bladder cancer survivor